Contrast Media Administration in Coronary Computed Tomography Angiography – A Systematic Review

Abstract

Background Various different injection parameters influence enhancement of the coronary arteries. There is no consensus in the literature regarding the optimal contrast media (CM) injection protocol. The aim of this study is to provide an update on the effect of different CM injection parameters on the coronary attenuation in coronary computed tomographic angiography (CCTA).

Method Studies published between January 2001 and May 2014 identified by Pubmed, Embase and MEDLINE were evaluated. Using predefined inclusion criteria and a data extraction form, the content of each eligible study was assessed. Initially, 2551 potential studies were identified. After applying our criteria, 36 studies were found to be eligible. Studies were systematically assessed for quality based on the validated Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-II checklist.

Results Extracted data proved to be heterogeneous and often incomplete. The injection protocol and outcome of the included publications were very diverse and results are difficult to compare. Based on the extracted data, it remains unclear which of the injection parameters is the most important determinant for adequate attenuation. It is likely that one parameter which combines multiple parameters (e. g. IDR) will be the most suitable determinant of coronary attenuation in CCTA protocols.

Conclusion Research should be directed towards determining the influence of different injection parameters and defining individualized optimal IDRs tailored to patient-related factors (ideally in large randomized trials).

Key points 

• This systematic review provides insight into decisive factors on coronary attenuation.

• Different and contradicting outcomes are reported on coronary attenuation in CCTA.

• One parameter combining multiple parameters (IDR) is likely decisive in coronary attenuation.

• Research should aim at defining individualized optimal IDRs tailored to individual factors.

• Future directions should be tailored towards the influence of different injection parameters.

Citation Format

• Mihl C, Maas M, Turek J et al. Contrast Media Administration in Coronary Computed Tomography Angiography – A Systematic Review. Fortschr Röntgenstr 2017; 189: 312 – 325

 

MissingLinkText

Zusammenfassung

Hintergrund Die Kontrastierung der Koronararterien in der CT wird durch verschiedene Parameter der Kontrastmittelinjektion beeinflusst. Bislang existiert in der Literatur kein allgemeingültiger Konsens zu einem optimalen Kontrastmittelinjektionsprotokoll. Das Ziel dieser Übersichtsarbeit war es, die vorhandene wissenschaftliche Literatur systematisch zu analysieren, um den Einfluss der verschiedenen Injektionsparameter zu bestimmen.

Methode Hierzu wurden peer-reviewed Studien analysiert, welche in Pubmed, Embase und MEDLINE zwischen Januar 2001 und Mai 2014 publiziert wurden. Mithilfe bestimmter vorher festgelegter Kriterien wurden in Frage kommende Studien evaluiert. Zu Beginn wurden 2551 mögliche Studien ausgewählt. Nach Analyse der Kriterien wurden letztendlich 36 Studien herausgefiltert, welche systematisch bezüglich ihrer Qualität mittels eines standardisiertem Bewertungsverfahren (Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-II checklist) beurteilt wurden.

Ergebnisse Innerhalb dieser Studien zeigte sich eine sehr heterogene und teils inkomplette Datenlage, was eine exakte Vergleichbarkeit sehr schwierig macht. Es bleibt weiterhin nicht in letzter Konsequenz zu beantworten, welcher Parameter entscheidend für eine optimale Kontrastierung der Koronararterien ist. Wahrscheinlich ist daher ein Parameter wie die Jodapplikationsrate (Iodine Delivery Rate) optimal, da dieser mehrere Faktoren (Kontrastkonzentration und Flussrate) miteinander verbindet.

Schlussfolgerung Da zukünftige Kontrastforschung sich auf eine verstärkt individualisierte Kontrastgabe richtet, sollten weitere (möglichst große randomisierte) Studien durchgeführt werden, welche die offenen Fragen bezüglich des Einflusses der einzelnen Parameter beantworten können.

Kernaussagen:

• Die vorliegende Arbeit gibt eine systematische Übersicht der entscheidenden Einflussfaktoren auf die optimale Kontrastierung der Koronarien.

• Verschiedene teils widersprüchliche Resultate wurden bislang in der Literatur bezüglich der Kontrastierung der Koronarien beschrieben.

• Die Jodapplikationsrate ist wahrscheinlich entscheidend, da dieser Parameter die zwei wichtigsten Faktoren miteinander kombiniert.

• Weitere Forschung ist notwendig, um die Jodapplikationsrate für den individuellen Patienten zu optimieren.

• Weitere Forschung ist notwendig, um den genauen Einfluss von verschiedenen Einzelfaktoren zu untersuchen.

 

MissingLinkText

Key words

cardiac - contrast agents - technical aspects - CT angiography

Introduction

Technical advances in coronary computed tomographic angiography (CCTA) continuously improved image quality [1]. Current technologies enable single-heartbeat CCTA with wide-area detectors [2], dual source technique or high pitch acquisition [3]. This leads to a substantial reduction in scan acquisition time (< 1 – 6 s, depending on scan protocol) as well as a decrease in motion artifacts due to breathing and coronary motion [4]. As these technical advances facilitate shorter scan acquisition times, smaller volumes of contrast media (CM) may be used (total iodine dose [TID]) [5] [6].

Previous studies demonstrated that enhancement levels in the coronary arteries above 325 Hounsfield units (HU) are necessary for optimal diagnosis [7] [8] [9]. Arterial attenuation depends on injection-related parameters (e. g. iodine delivery rate [IDR; gI/s], injection rate [ml/s], CM concentration [mg/ml], TID, CM volume, viscosity, saline flush, temperature of injected CM and injection needle type), scan-related parameters (e. g. scan protocol, scan duration, scan delay, tube voltage, and reconstruction parameters [kernel]) and patient-related factors (e. g. cardiac output, blood volume, heart rate, breath hold and weight) [1] [10] [11]. The influence of these individual parameters is important as future directions are aimed towards more individualized CM injection protocols. Previous research has focused on the influence of saline flush, IDR, injection rate, CM concentration, injection needle size, CM volume, viscosity as well as the temperature of injected CM on intravascular attenuation with various outcomes [1] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20]. Specifically, the influence of CM concentration has been studied extensively, and current evidence is controversial as to whether a more highly concentrated CM is beneficial in intravascular attenuation, when the calculated IDR (e. g. CM concentration × injection rate) is kept identical [12] [15] [16] [18] [19] [20]. To date, there is no consensus regarding the decisive injection parameters influencing attenuation of the coronary arteries.

A systematic review of the literature on current CM application protocols for CCTA was performed with the aim of providing an overview of the influence of various injection factors on enhancement of the coronary arteries with a special focus on IDR, CM concentration and injection rate.

 

MissingLinkText

Methods

Data sources and study selection

For this systematic review, we conducted a search through PubMed, Embase and MEDLINE between January 2001 and May 2014 using the search terms coronary computed tomography angiography, coronary computed tomography, iodine delivery rate, coronary attenuation, coronary enhancement, total iodine load, coronary arteries, iodine concentration, contrast media concentration, contrast material concentration.

Inclusion criteria were: (1) studies had to compare different CM injection protocols in CCTA by providing attenuation levels in the coronaries achieved by a specific infusion protocol, (2) an evaluation of image quality and/or diagnostic accuracy was reported, (3) sample size of ≥ 30 (> 18 years old), (4) language English, German or French, (5) MDCT ≥ 16 slice and (6) IDR, injection rate, CM concentration, TID, CM volume had to be deduced. Studies conducted primarily on radiation dosage, other technical aspects (e. g. reconstruction kernels, bolus tracking technique/test bolus method), central venous or intra-arterial CM delivery, or focusing on patients with stents or bypasses were excluded. Three readers (CM, JT, AS) independently performed the searches and assessed the eligibility of the studies by reading the abstract and application of these criteria. All potentially eligible articles were screened for references to additional eligible studies. Disagreement on inclusion was solved by consensus between the three readers.

 

MissingLinkText

Data extraction

Publications considered eligible were scored using a standardized extraction form, for the following variables: design (retrospective/prospective/both), population region/size, age, weight/body mass index (BMI), height, heart rate, cardiac output, blood pressure, MDCT technique, slice collimation, rotation time, acquisition mode, kV settings, reconstructed slice thickness, reconstruction kernel, intravenous (i. v.) needle size, CM concentration, CM volume, injection rate, injection duration, saline flush, injection pattern, temperature, IDR, TID and enhancement level at different coronary arteries.

In addition, the quality of the studies regarding selection and inclusion criteria, study aims, patient characteristics and methodology was assessed and a flowchart was created according to the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines [21]. Studies were also systematically assessed for quality based on the validated Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-II checklist [22]. This checklist assesses the risk of bias and clinical applicability of studies based on different domains. Some of the domains are not applicable to the included studies, as this review does not focus on strict diagnostic studies. Therefore, only domains relevant to our study were selected from QUADAS-II for quality assessment. Results from the QUADAS-II assessment are depicted in a graphical manner.

Additionally, the corresponding authors of all included studies were contacted to fill out a questionnaire providing additional parameters that could not be retrieved from the publication. The large heterogeneity observed between the included studies regarding patient population, scanning technique and infusion parameters precluded us from pooling the data and only allowed a systematic review. To account for heterogeneity with regard to the outcome measure, a subgroup analysis of the most frequently studied anatomical location (RCA) was performed (e. g. 30 studies) to evaluate the influence of injection-related parameters on coronary attenuation. Since this study is a systematic literature review, no approval from our institutional review board was necessary.

 

MissingLinkText

 

MissingLinkText

Results

In the primary literature search, 5007 potential studies (Pubmed: 2457, Embase: 1734, Medline: 816) were identified, of which 2456 were duplicates, leaving 2551 potential studies for analysis. 2403 studies were excluded from further evaluation after scanning of the abstract. Of the remaining 148 studies, 91 studies did not meet the eligibility criteria and were further excluded, leaving 57 studies to be reviewed using the extraction form and consensus reading. Another 21 studies were excluded as they addressed other technical aspects or because basic inclusion criteria and/or injection parameters could not be derived [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43]. In total, 36 studies were included with a total of 4339 patients [7] [15] [16] [19] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75]. Of the included studies, 18 authors responded to the questionnaire [7] [19] [49] [51] [54] [55] [56] [57] [60] [61] [63] [64] [65] [66] [67] [70] [72] [75]. A detailed overview of the inclusion and data extraction process is depicted in [Fig. 1].

Fig. 1 Detailed overview study selection.

Abb. 1 Detail Übersicht zu den ausgewählten Studien.

Data was prospectively collected in the vast majority (81 %) of the included studies. According to the QUADAS-II assessment, there were some concerns regarding the risk of bias and applicability mainly in the domain regarding patient selection. For the other domains a low risk of bias was found. Results of the QUADAS-II assessment are shown in [Fig. 2]. The quality assessment of all included publications is presented in the supplemental material.

Fig. 2 Graphical display of different domains of the QUADAS II checklist for all included studies (n = 36).

Abb. 2 Grafische Darstellung der QUADAS-II-Domänen der eingeschlossenen Studien (n = 36).

Scan and patient-related parameters are described in [Table 1], [2]. Baseline characteristics were poorly described, only reporting mean age, heart rate and weight. Approximately 20 publications state one or more additional baseline characteristics (e. g. BMI, cardiac output or blood pressure) [7] [48] [52] [54] [55] [56] [57] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75]. In the vast majority of the included publications, a tube voltage of 120 kV was used. Some of the included papers either did not mention tube voltage or mention lower or various kV settings [48] [59] [63] [70] [73] [74]. As different vendors and scanners were used, scan-related parameters such as collimation, slice reconstruction and kernel were not comparable and occasionally missing.

Table 1 Scan characteristics of the included studies listed according to year of publication.
Tab. 1 Scan-Parameter der eingeschlossenen Studien. Reihenfolge nach Jahr der Publikation.

author	coll (mm)	rot time (ms)	acquisition mode	kV setting	slice reconstr (mm)	kernel
Cademartiri [44]	12x× 0.75	420	ECG gating	120	1	medium smooth (B30f)
Cademartiri [15]	16 × 0.75	420	ECG gating	120	1	medium smooth (B30f)
Cademartiri [45]	16 × 0.75	420	ECG gating	120	1
Cademartiri [16]	16 × 0.75	375	ECG gating	120	1	medium smooth (B30f)
Rist [19]	16 × 0.75	375	ECG gating	120	1	B20f
Utsunomiya [46]	16 × 0.5	400	ECG gating	120
Yamamuro [47]	64 × 0.5	400		120	0.5
Husmann [48]	64 × 0.625	350	ECG triggering
Kerl [49]	2 × 32 × 0.6	330	ECG gating	120	0.75	medium smooth (B25f)
Kim [50]	64 × 0.6	370	ECG gating	120		medium smooth (B25f)
Nakaura [51]	64 × 0.625	420	ECG gating	120	0.67	medium cardiac
Tsai [52]	40 × 0.625	420	ECG gating	120	1.4 – 3
Wuest [53]	64 × 0.6	330	ECG gating	120	0.75	medium sharp (B26f)
Halpern [54]	64 × 0.9	420	ECG gating/triggering	120	0.8	cardiac sharp C
Seifarth [55]	2 × 32 × 0.6	330		120
Kim [56]	64 × 0.5	400	ECG gating	120	0.5	FC43
Lu [57]	64 × 0.625	350	ECG gating	120
Ozbulbul [58]	16 × 0.625	500	ECG gating	120	0.625	medium soft tissue
Pazhenkottil [59]	64 × 0.625	350	ECG triggering	100 – 120	0.625
Tatsugami [60]	320 × 0.5	350/375	ECG gating	120	0.5	FC13
Tatsugami [61]	64 × 0.5	350/400	ECG triggering	135	0.5	FC13
Becker [62]		330	ECG gating	120	0.6	B26
Isogai [7]	64 × 0.625	350	ECG gating	120	0.625	cardiac
Kumamaru [63]	320 × 0.5	350	ECG triggering	80/100/120		FC03
Nakaura [64]	64 × 0.625	420	ECG gating	120	0.67	medium cardiac (XCB)
Zhu [65]	2 × 64 × 0.6	330	ECG gating	120	0.75	medium soft tissue (B26f)
Zhu [66]	2 × 64 × 0.6	330	ECG gating	120	0.75	medium soft tissue (B26f)
Zhu [67]	2 × 64 × 0.6	330	ECG gating	120	0.75	medium soft tissue (B26f)
Kidoh [68]	64 × 0.625	420	ECG gating	120	0.67	medium cardiac (XCB)
Kidoh [69]	64 × 0.625	420	ECG gating	120	0.67	medium cardiac (XCB)
Liu [70]	2 × 128 × 0.6	280	ECG triggering	100	0.75	medium smooth (B26)
Yang [71]	2 × 128 × 0.6	280	ECG triggering	120	0.6	media smooth (B26f)
Tomizawa [72]	320 × 0.5	350/375/400	ECG triggering	120	0.5	FC04, AIDR
Zheng [73	2 × 64 × 0.6	280	ECG triggering	80/100 100/120	0.75	I26F B26f
Lembcke [74]	2 × 128 × 0.6	280	ECG triggering	100
Kawaguchi [75]	2 × 128 × 0.625	270	ECG gating	120	0.8	medium cardiac (XCB)

Coll: collimation, rot: rotation, reconstr: reconstruction, BMI: body mass index.
Coll: Kollimation, Rot: Rotation, Reconstr.: Rekonstruktion, BMI: Body Maß Index.

Table 2 Patient characteristics of the included studies listed according to year of publication.
Tab. 2 Patienten Charakteristika der eingeschlossenen Studien. Reihenfolge nach Jahr der Publikation.

author	no. of subjects (m;f)	mean age (years)	mean weight (kg)	BMI (kg/m2)	heart rate (bpm)	CO (l/min)/EF (%)	BP (syst; diast, mmHg)
Cademartiri [44]	21 (16;5)	59 (34 – 74)	72 (53 – 90)		60 (48 – 72)
	21 (14;7)	59 (39 – 79)	74 (60 – 95)		60 (49 – 80)
Cademartiri [15]	25 (22;3)	58 ± 11	74 ± 7		59 ± 8
	25 (20;5)	60 ± 11	72 ± 7		59 ± 7
	25 (21;4)	58 ± 13	72 ± 7		61 ± 9
	25 (21;4)	57 ± 11	74 ± 9		60 ± 9
	25 (20;5)	63 ± 12	71 ± 8		57 ± 8
Cademartiri [45]	15 (11;4)	58 (34 – 74)	71 (55 – 90)		58 (46 – 72)
	15 (14;1)	58 (28 – 73)	72 (60 – 88)		56 (45 – 65)
	15 (14;1)	59 (45 – 79)	73 (60 – 95)		56 (45 – 68)
Cademartiri [16]	20 (15;5)	59 ± 12	73 ± 9		61 ± 7
	20 (14;6)	63 ± 10	75 ± 11		60 ± 8
Rist [19]	30	58.13 ± 11.16	77.68 ± 14.76		57.3 ± 3.7
	30	62.17 ± 8.22	84.86 ± 16.24		57.4 ± 4.3
Utsunomiya [46]	13 (total: 30;8)	68.6 ± 8.4	59.5 ± 7.0		61 ± 11
	12	63.9 ± 8.9	62.1 ± 8.5		59 ± 11
	13	68.0 ± 8.8	64.3 ± 7.1		58 ± 8
Yamamuro [47]	30 (16;14)	68.7 ± 12.1	59.5 ± 11.7		70.1 ± 13.1
	30 (17;13)	68.0 ± 11.0	57.3 ± 7.8		72.7 ± 18
Husmann [48]	70 (48;22)	58 ± 12	79 ± 16	26.5 ± 4.0	57.7 ± 7.0
	70 (51;19)	60 ± 11	80 ± 15	26.7 ± 4.2	57.6 ± 6.0
Kerl [49]	25 (14;11)	53.32	82.2
	25 (20;5)	65.40	87.7
	25 (14;11)	65.84	86.9
Kim [50]	20 (total: 59;41)	62 (44 – 82)	62 (54 – 78)		55 (42 – 67)
	20	56 (43 – 76)	67 (53 – 79)		58 (47 – 74)
	20	57 (37 – 76)	61 (51 – 75)		59 (43 – 79)
	20	58 (39 – 77)	64 (53 – 79)		58 (41 – 71)
	20	57 (38 – 72)	66 (52 – 83)		61 (51 – 74)
Nakaura [51]	30 (13;17)	62.4 ± 12.5	60.1 ± 14.2		66.5 ± 12.5
	30 (16;14)	67.5 ± 12.9	59.5 ± 12.8		65.8 ± 12.9
Tsai [52]	38 (22;16)	61.7 ± 12.5	64.9 ± 10.9		71.5 ± 13.2	58.8 ± 6.5	120.7 ± 14.5; 75.4 ± 10.5
	34 (21;13)	61.7 ± 11.3	65.9 ± 8.4		76.7 ± 11.2	57.0 ± 5.6	118.9 ± 12.6; 75.8 ± 9.0
Wuest [53]	53 (38;15)	58 ± 11.82
	53 (40;13)	62 ± 13.08
Halpern [54]	260 (%: 57;43)	58 ± 12	89 ± 25	30.3 ± 7.6	61.5 ± 0.8		Syst> 100
	168 (%: 45;55)	50 ± 12	85 ± 21	29.6 ± 6.7	63.0 ± 1.0
Seifarth [55]	40	62.3 ± 10.8	80.8 ± 14.2	26.3 ± 3.0	64.7 ± 13.0
	40	62.6 ± 9.6	82.0 ± 13.4	26.2 ± 3.7	63.1 ± 11.4
	40	62.9 ± 13.3	81.7 ± 15.3	26.3 ± 3.8	63.7 ± 13.3
Kim [56]	151 (87;64)	55 ± 9	67 ± 10.2	24.6 ± 3.0	70 ± 11		124 ± 18 (85 – 169)
	146 (88;58)	52 ± 11	68 ± 9.9	24.8 ± 2.7	71 ± 11		128 ± 19 (92 – 181)
Lu [57]	30 (total: 71;79)	55.6 ± 10.9		23.4 ± 2.4	58.0 ± 8.0
	30	58.8 ± 12.2		23.8 ± 2.6	58.4 ± 6.3
	30	58.8 ± 10.5		23.7 ± 2.5	57.9 ± 7.5
	30	58.3 ± 11.5		23.5 ± 2.3	57.6 ± 6.7
	30	56.1 ± 11.2		24.3 ± 2.5	56.1 ± 6.8
Ozbulbul [58]	24 (total: 20;32)	56.4 ± 13.6			61.0 ± 8.9
	28	54.1 ± 17.1			62.8 ± 7.0
Pazhenkottil [59]	80 (59;21)	59 ± 11	82 ± 12		56 ± 7
	80 (68;12)	57 ± 11	82 ± 12		56 ± 7
Tatsugami [60]	48 (57;41)	69.8 ± 9.8	59.3 ± 8.4		57.1 ± 9.7
	50	68.7 ± 9.0	58.0 ± 8.1		58.8 ± 6.4
Tatsugami [61]	16 (total: 27;18)	68.2 ± 10.6	57.4 ± 6.0		53.8 ± 7.6
	15	69.1 ± 10.3	55.3 ± 5.9		55.7 ± 7.7
	14	69.6 ± 9.6	56.2 ± 7.8		59.0 ± 12.2
Becker [62]	50 (28)	57.0 ± 11.2	77.4 ± 17.7		66.5 ± 14.26
	54 (31)	60.4 ± 11.6	78.0 ± 19.1		68.1 ± 15.86
Isogai [7]	20 (16;4)	63.5 ± 11.4	63.9 ± 13.7		62.1 ± 10.9		133.8 ± 14.3; 79.9 ± 8.8
	20 (12;8)	64.4 ± 11.7	64.4 ± 13.3		63.0 ± 8.2		133.± 17.9; 82.0 ± 11.8
	20 (5;15)	65.4 ± 7.8	66.0 ± 8.5		62.9 ± 10.5		138.3 ± 16.9; 80.6 ± 12.7
Kumamaru [63]	36 (18;18)	56.7 ± 12.9	79.7 ± 15.4	22.8 ± 4.8	57.4 ± 5.9
	72 (41;31)	54.8 ± 11.9	80.8 ± 18.0	27.8 ± 4.8	56.7 ± 5.9
Nakaura [64]	30 (21;9)	69.9 ± 9.1	56.8 ± 9.2	22.4 ± 3.1	60.0 ± 9.7	4.2 ± 0.9
	30 (20;10)	70.9 ± 11.6	57 ± 10	22.9 ± 3	59.8 ± 10.9	4.2 ± 1.0
Zhu [65]	96 (57;39)	58.2 (29 – 85)	67.1 (39 – 101)	24.5 (15.8 – 34)	71.7 (48 – 106)	6.2 ± 1.7
	100 (53;47)	58.1 (27 – 84)	67.9 (40 – 101)	24.6 (17.9 – 35.4)	74.5 (51 – 107)
	100 (53;47)	59.8 (30 – 83)	65.9 (41 – 104)	24.1 (15.2 – 34.9)	73.0 (50 – 104)
Zhu [66]	114 (60;54)	60.8 (30 – 85)	66.9 (34 – 100)	24.7 (16.4 – 32.7)	74.5 (49 – 107)
	119 (67;52)	59.8 (28 – 83)	67.1 (38 – 94)	24.7 (16.9 – 32.0)	75.7 (50 – 111)
Zhu [67]	113 (60;53)	58.2 (30 – 85)	66.9 (34 – 100)	24.7 (16.4 – 32.7)	74.5 (49 – 107)
	94 (54;40)	60.4 (32 – 87)	64.8 (42 – 101)	23.9 (16.4 – 33.0)	74.3 (37 – 106)
Kidoh [68]	50 (32;18)	70.7 ± 9.5	57.2 ± 10.4	22.6 ± 3.2	60.1 ± 10.3	4.2 ± 1.5
	50 (32;18)	68.5 ± 11.4	56.8 ± 10.2	22.3 ± 2.9	60.6 ± 11.8	4.1 ± 1.2
Kidoh [69]	30 (18;12)	68.1 ± 12	57.7 ± 13.3		64.1 ± 11.0	4.6 ± 1.3
	30 (21;9)	59.9 ± 14.3	61.6 ± 10.0		62.8 ± 11.4	4.6 ± 1.2
Liu [70]	30 (total: 60;30)	55 ± 13	71 ± 12	25.0 ± 2.8	56 ± 6	> 55 %	150;80
	30	59 ± 10	71 ± 9	24.9 ± 2.4	58 ± 5
	30	52 ± 11	73 ± 13	25.3 ± 3.2	57 ± 5
Yang [71]	120 (81;39)	58.5 ± 9.8	68.7 ± 11.1	24.1 ± 3.0	59.1 ± 7.5
	80 (53;27)	59.6 ± 9.7	69.0 ± 10.1	23.7 ± 2.8	59.3 ± 6.8
Tomizawa [72]	36 (20;16)	66.1 ± 14.4	59.3 ± 12.1	23 ± 3.6	67.5 ± 11.5
	36 (16;20)	67.9 ± 12.6	55.9 ± 8.8	22.3 ± 3.0	65.8 ± 13.6
	36 (17;19)	67.1 ± 9.8	61.3 ± 13.7	23.7 ± 3.2	57.4 ± 11.2
Zheng [73]	50 (25;25)	54.53 ± 10.71	65.45 ± 11.13	22.31 ± 2.77	75.61 ± 9.59
	25 (12;13)	BMI< 25: 56.39 ± 12.79	BMI< 25: 57.57 ± 6.65	BMI< 25: 20.9 ± 1.49	BMI< 25: 75.35 ± 10.13
	25(13;12)	BMI≥ 25: 52.88 ± 8.39	BMI≥ 25: 72.42 ± 9.56	BMI≥ 25: 25.44 ± 1.63	BMI≥ 25: 75.85 ± 9.29
	50 (31;19)	55.24 ± 9.38	64.55 ± 12.91	23.73 ± 3.39	72.67 ± 9.89
	25 (12;13)	BMI< 25: 58.56 ± 9.43	BMI< 25: 54.28 ± 6.36	BMI< 25: 20.79 ± 1.32	BMI< 25: 72.76 ± 10.49
	25 (19;6)	BMI≥ 25: 52.04 ± 8.30	BMI≥ 25: 74.42 ± 9.35	BMI≥ 25: 26.56 ± 2.09	BMI≥ 25: 72.58 ± 9.49
Lembcke [74]	20 (8;12)	75.7 ± 7.4	76 ± 7.8	25.9 ± 2.9
	20 (13;7)		76.1 ± 8.1	25.2 ± 2.2
	20 (8;12)		76.6 ± 6.6	26.4 ± 2.6
	20 (9;11)		74.5 ± 7.1	25.9 ± 2.1
	20 (10;10)		75.9 ± 8.0	26.2 ± 2.5
Kawaguchi [75]	50 (32;18)	63.3 ± 12	64.7 ± 11.1	24.6 ± 3.5	66.1 ± 11.7
	50 (27;23)	65.3 ± 11.5	62.5 ± 12.7	24.1 ± 3.8	63.7 ± 7.2

M: male, F: female, kg: kilograms, BMI: body mass index, BPM: beats per minute, CO: cardiac output, EF: ejection fraction, BP: blood pressure, syst: systolic, diast: diastolic.
M: männlich, F: weiblich, kg: Kilogramm, BMI: Body Maß Index, BPM: Beats pro Minute, CO: Kardialer Output, EF: Ejektion Fraktion, BP: Blutdruck, Syst.: Systole, Dias: Diastole.

Injection-related parameters are described in [Table 3]. The temperature of the injected CM concentration was only stated in a limited number of publications [15] [19] [52] [56] [58] [60] [61] [62] [65] [66] [67] [72]. A saline flush was initially not used in all injection protocols but has gained increasing popularity in more recent publications with only a few publications using injection protocols without a saline flush [44] [45] [46] [49] [57] [58] [72]. Only eight publications state usage of a biphasic protocol, often in comparison to a uniphasic injection protocol [45] [46] [47] [49] [53] [54] [55] [57]. The total injected CM volume ranged between 30 ml and 140 ml. Within the period of inclusion, a gradual decrease in total injected CM volume is noted, as earlier publications make mention of a total injected CM volume of 140 ml [15] [44] [45], whereas more recent publications reported CM injection protocols with total injected CM volumes below 40 ml [69] [70] [74] [75]. Subsequently, the TID has substantially lowered from anywhere between 44 – 56 g [15] [44] [45] to less than 15 g (range: 11.1 – 56.0 g) [7] [47] [60] [61] [64] [68] [69] [70] [71].

Table 3 Injection parameters of the included studies listed according to year of publication.
Tab. 3 Kontrastinjektionsparameter der eingeschlossenen Studien. Reihenfolge nach Jahr der Publikation.

author	needle	CM (mg/ml)	CM volume (ml)	flow rate (ml/s)	saline	injection pattern	temp (°C)	IDR (gI/s)	TID (g)
Cademartiri [44]	18G	iodixanol 320	140	4	no	uniphasic		1.28	44.8
		iodixanol 320	100	4	yes	uniphasic		1.28	32
Cademartiri [15]	18G	iohexol 300	140	4	no	uniphasic		1.2	42
		iodixanol 320	140	4	no	uniphasic	37	1.28	44.8
		iohexol 350	140	4	no	uniphasic	37	1.4	49
		iomeprol 350	140	4	no	uniphasic	37	1.4	49
		iomeprol 400	140	4	no	uniphasic	37	1.6	56
Cademartiri [45]	18 – 20G	iodixanol 320	140	4	no	uniphasic		1.28	44.8
		iodixanol 320	140	5→3	no	biphasic		1.6→0.96	44.8
		iodixanol 320	100	4	no	uniphasic		1.28	32
Cademartiri [16]	18G	iopromide 370	100	4	yes	uniphasic		1.48	37
		iomeprol 400	100	4	yes	uniphasic		1.6	40
Rist [19]	18G	iomeron 300	83	3.3	yes	uniphasic	37	0.99	24.9
		iomeron 400	63	2.5	yes	uniphasic	37	1.0	25.2
Utsunomiya [46]	20G	iohexol 350	60 + mix 80 (50 %)	3→1.5	no	biphasic		1.05→0.26	35
		iohexol 350	100	3	yes	uniphasic		1.05	35
		iohexol 350	100	3	no	uniphasic		1.05	35
Yamamuro [47]		iomeron 350	40	3.5→2.8	yes	biphasic		1.23→0.98	14
		iomeron 350	50	3.5→2.8	yes	biphasic		1.23→0.98	17.5
Husmann [48]	18G	iodixanol 320	80	5	yes	uniphasic		1.6	25.6
		iodixanol 320	73.9 ± 11.2	4.0 – 5.0	yes	uniphasic		1.28 – 1.6	23.6
Kerl [49]	18G	iopamidol 370	50 – 75	5	no	uniphasic		1.85	18.5 – 27.8
		iopamidol 370	50 – 75	5	yes	uniphasic		1.85	18.5 – 27.8
		iopamidol 370	(50 – 75) + mix 50 (30 %)	5	yes	biphasic		1.85→0.56	18.5 – 27.8 + 5.6
Kim [50]		iobitridol 350	60	4	yes	uniphasic		1.4	21
		iobitridol 350	60	4	yes	uniphasic		1.4	21
		iobitridol 350	60	4	yes	uniphasic		1.4	21
		iobitridol 350	60	4	yes	uniphasic		1.4	21
		iobitridol 350	60	4	yes	uniphasic		1.4	21
Nakaura [51]	20G	iopamiron 370	80	4	yes	uniphasic		1.48	29.6
		iopamiron 370	59.5 ± 12.8	3.96 ± 0.85	yes	uniphasic		1.47	22.0 ± 4.7
Tsai [52]	20G	iohexol 350	100	4	yes	uniphasic	37	1.4	35
		iodixanol 320	100	4	yes	uniphasic	37	1.28	32
Wuest [53]		iomerol 350	45 – 65	5	yes	uniphasic		1.75	15.75 – 22.75
		iomerol 350	55 – 75 (incl mix 20 %)	5	yes	biphasic		1.75→0.35	22.75 – 29.75
Halpern [54]	18 – 20G	ioversol 350	70	5.5	yes	uniphasic		1.93	24.5
		ioversol 350	70 + mix 50 (50 %)	5	yes	biphasic		1.75→0.88	33.25
Seifarth [55]	18G	iopromide 370	80 + mix 50 (30 %)	6	yes	biphasic		2.22→0.67	35.2
		iopromide 370	82.5 ± 8.8 + mix 34.3 ± 10.8(30 %)	5.1 ± 0.6	yes	biphasic		1.89→0.57	35.6
		iopromide 370	73.5 ± 12.9 + mix 50 (30 %)	5	yes	biphasic		1.85→0.56	32.8
Kim [56]	18G	iomeprol 370	70	4	yes	uniphasic	37	1.48	25.9
		iomeprol 400	70	4	yes	uniphasic	37	1.6	28
Lu [57]	20G	iohexol 350	67 ± 5.3	5	no	uniphasic		1.75	23.45
		iohexol 350	59.9 ± 4.9	5	yes	uniphasic		1.75	20.97
		iohexol 350	(56.9 ± 3.2) + mix 20 (30 %)	5	yes	biphasic		1.75→0.53	22.02
		iohexol 350	(59.2 ± 5.7) + mix 20 (50 %)	5	yes	biphasic		1.75→0.88	24.22
		iohexol 350	(56.9 ± 4.6) + mix 20 (70 %)	5	yes	biphasic		1.75→1.23	24.82
Ozbulbul [58]	18G	iodixanol 320	130	4	no	uniphasic	37	1.28	41.6
		iopamidol 370	130	4	no	uniphasic	37	1.48	48.1
Pazhenkottil [59]	18G	iodixanol 320	80	5	yes	uniphasic		1.6	25.6
		iodixanol 320	70.9 ± 14.1	3.5 – 5.0	yes	uniphasic		1.1 – 1.6	22.7
Tatsugami [60]	20G	iomeron 350	47.5 ± 7.4	4 ± 0.56	yes	uniphasic	37	1.4	16.6
		iomeron 350	41.5 ± 5.5	4.06 ± 0.57	yes	uniphasic	37	1.42	14.5
Tatsugami [61]	20G	iomeron 350	46.5 ± 5.25	3.3 ± 0.37	yes	uniphasic	37	1.16	16.28
		iomeron 350	44.3 ± 4.71	4.4 ± 0.48	yes	uniphasic	37	1.54	15.5
		iomeron 350	39.3 ± 5.41	4.0 ± 0.55	yes	uniphasic	37	1.40	13.76
Becker [62]	18G	iodixanol 320	80	5	yes	uniphasic	37	1.6	25.6
		iomeprol 400	80	5	yes	uniphasic	37	2	32
Isogai [7]	18G	iohexol 300	44.7	4.5	yes	uniphasic		1.35	13.42
		iohexol 350	38.6	3.9	yes	uniphasic		1.37	13.52
		iohexol 350	46.2	4.6	yes	uniphasic		1.61	16.17
Kumamaru [63]	20G	iopamidol 370	60	6	yes	uniphasic		2.22	22.2
		iopamidol 370	80	6	yes	uniphasic		2.22	29.6
Nakaura [64]	20G	iohexol 350	57 ± 10.1	3.8 ± 0.7	yes	uniphasic		1.33 ± 0.23	20
		iohexol 350	39.7 ± 6.4	4.4 ± 0.7	yes	uniphasic		1.55 ± 0.25	13.9
Zhu [65]	20G	iopromide 370	66.3 (42 – 92)	4.15 (2.6 – 5.7)	yes	uniphasic	37	1.54	24.5
		iopromide 370	66.4 (40 – 92)	4.19 (2.6 – 6)	yes	uniphasic	37	1.55	24.6
		iopromide 370	66.4 (37 – 95)	4.08 (2.7 – 5.9)	yes	uniphasic	37	1.51	24.6
Zhu [66]	20G	iopromide 370	73.6 ± 13.5	4.69 ± 0.95	yes	uniphasic	37	1.74	27.23
		iopromide 370	67.9 ± 8.3	4.38 ± 0.66	yes	uniphasic	37	1.62	25.12
Zhu [67]	20G	iopromide 370	73.6 (37 – 110)	4.69 (2.3 – 7.4)	yes	uniphasic	37	1.74	27.2
		iopromide 370	68.5 (42 – 111)	4.37 (2.5 – 6.6)	yes	uniphasic	37	1.62	25.3
Kidoh [68]	20G	iohexol 350	40.6 ± 7.6	4.5 ± 0.9	yes	uniphasic		1.58	14.21
		iohexol 350	39.7 ± 7.1	5	yes	uniphasic		1.75	13.90
Kidoh [69]	20G	iohexol 350	36.9 ± 9.2	4.1	yes	uniphasic		1.44	12.92
		iohexol 350	43.1 ± 7.0	4.8	yes	uniphasic		1.68	15.09
Liu [70]	18G	iopromide 370	47 ± 8	5.0/6.0	yes	uniphasic		1.85/2.22	17.39
		iopromide 370	44 ± 8	5.0/6.0	yes	uniphasic		1.85/2.22	16.28
		iopromide 370	36 ± 6	5.0/6.0	yes	uniphasic		1.85/2.22	13.32
Yang [71]	18G	iopamidol 370	30 – 60	4	yes	uniphasic		1.48	11.1 – 22.2
		iopamidol 370	60	4	yes	uniphasic		1.48	22.2
Tomizawa [72]	20 – 22G	iopamidol 370	49.3 ± 10.1	3.5 ± 0.7	no	uniphasic	37	1.3	18.24
		iopamidol 370	46.8 ± 7.6	3.3 ± 0.5	yes	uniphasic	37	1.22	17.32
		iopamidol 370	43.9 ± 9.6	3.6 ± 0.8	yes	uniphasic	37	1.33	16.24
Zheng [73]	18G	iodixanol 270	65.5 ± 11.1	5	yes	uniphasic		1.35	17.69
		iopromide 370	64.6 ± 12.9	5	yes	uniphasic		1.85	23.9
Lembcke [74]	18G	iopromide 370	30	5	yes	uniphasic		1.85	11.1
		iopromide 370	40	5	yes	uniphasic		1.85	14.8
		iopromide 370	50	5	yes	uniphasic		1.85	18.5
		iopromide 370	60	5	yes	uniphasic		1.85	22.2
		iopromide 370	70	5	yes	uniphasic		1.85	25.9
Kawaguchi [75]	20G	iohexol 350 or iopamidol 370	38.6 ± 7.6 43.9 ± 6.9	5	yes	uniphasic		1.75 or 1.85	14.8 ± 2.9
		iopamidol 370	37.6 ± 7.6	3.7 ± 0.7	yes	uniphasic		1.37	13.9 ± 2.8

CM: contrast media, mg: milligram, ml: milliliter, s: second, mix: mixed bolus (presented as total volume of mixed bolus), %: percentage of CM in mixed bolus, → indicates second injection phase, IDR: iodine delivery rate, TID: total iodine dose.
CM: Kontrastmittel, mg: Milligramm, ml: Milliliter, s: Sekunde, mix: Mischbolus (angegeben als Gesamtvolumen), %: Prozent Kontrastmittel im Mischbolus, → Indiziert eine zweite Injektionsphase, IDR: Iodine Delivery Rate (Jodapplikationsrate), TID: Totale-Jod-Dosis.

Injection-related parameters and coronary attenuation

The results of all included publications in relation to its three major injection parameters are presented in the supplemental material. The CM concentration varied between 270 mg/ml and 400 mg/ml. However, only four CM injection protocols make use of CM concentrations below 320 mg/ml [7] [15] [19] [73]. The variation in injection rate was higher than for CM concentrations, varying between 2.5 ml/s [19] and 6 ml/s [55] [63] [70]. The majority of the included papers keep injection rate relatively constant when comparing different groups. Only a few studies mention substantial differences in flow rates between groups [19] [55] [61] [75]. IDR ranged between 0.99gI/s and 2.22gI/s and proved to be very heterogeneous. A limited number of injection protocols stated usage of an IDR above 1.9gI/s [54] [55] [63] [70]. All included publications that stated a flow rate below 4 ml/s also reported an IDR < 1.4gI/s [7] [46] [47] [61] [64] [75]. However, lower CM concentrations were not always associated with lower IDR levels, as some publications state IDR levels ≥ 1.4gI/s with usage of lower (e. g. 320 mg/ml) CM concentrations, indicating that the CM injection rate might have a greater influence on the calculated IDR [45] [48] [59].

Conflicting results were reported with regard to the influence of IDR on coronary attenuation. When the IDR differed between subgroups, various publications found significant differences in the attenuation of the coronary arteries in favor of a higher IDR [7] [15] [16] [55] [61] [62] [68] [69] [75]. When the IDR between subgroups was kept identical, numerous publications did not find statistically significant differences in coronary attenuation [7] [15] [19] [44] [45] [46] [49] [51] [60] [70] [71]. In both groups (variable and identical IDR), other injection-related parameters varied substantially, making it difficult to determine the true influence of IDR on coronary attenuation [47] [50] [53] [55] [57] [63] [74]. Three studies report significant differences between CM concentrations in favor of higher CM concentrations [15] [16] [62]. However, other injection parameters such as IDR were not kept identical between groups.

Diagnostic attenuation levels of the RCA were reached in the vast majority of the included studies when IDR levels ≥ 1.4gI/s were used. Only seven studies report non-diagnostic attenuation levels of the RCA with usage of an IDR ≥ 1.4gI/s [16] [45] [46] [47] [49] [54] [58], of which four studies report the lack of usage of a saline chaser [45] [46] [49] [58]. When no saline flush was applied, almost all publications report attenuation values of the RCA below a diagnostic level (< 325HU), stressing the importance of a saline chaser [44] [45] [46] [49] [58].

 

MissingLinkText

 

MissingLinkText

Discussion

The aim of this systematic review was to provide an update on the effect of different CM injection parameters on the attenuation in CCTA. A large variation regarding scan technique, patient characteristics and CM injection protocols was found. This heterogeneity makes it difficult to draw conclusions and stresses the need for studies in which such heterogeneity is avoided.

The findings in this systematic review confirm the need for an additional saline flush in a CM injection protocol. A saline flush pushes the tail of the injected CM bolus into the central blood volume thus utilizing CM that would otherwise remain behind in the injection tubing and peripheral veins [4]. Cademartiri et al. divided patients into two groups: group 1 (140 ml at 4 ml/s, no saline flush) and group 2 (100 ml at 4 ml/s followed by 40 ml of saline chaser at 4 ml/s) with an identical IDR (1.28gI/s). No significant differences in the attenuation of the coronary arteries were found [44]. As group 1 did not receive a saline flush, it is quite possible that some of the injected CM bolus was not dispensed into the central blood volume, leading to a decrease in the effective CM volume and subsequently to the non-significant differences in intracoronary attenuation.

The influence of CM concentration solely on attenuation has been an ongoing topic of interest. The majority of the included studies evaluating differences in CM concentrations did not find statistically significant differences in attenuation between groups [19] [52] [56] [58]. Some studies do attribute higher attenuation to higher CM concentrations [15] [16] [62]. Becker et al. conducted a double-blind multicenter randomized controlled trial, which randomized patients in 2 CM groups (iodixanol 320 mg/ml and iomeprol 400 mg/ml) in order to assess whether CM characteristics affect diagnostic quality. In both groups 80 ml CM was injected at an identical injection rate of 5 ml/s [62]. A significant difference was found in coronary attenuation in favor of the 400 mg/ml group. They concluded that CM with a higher iodine concentration was beneficial to attenuation when administered at an identical injection rate and volume. However, administering different CM concentrations at an identical injection rate leads to differences in IDRs (320 mg/ml: 1.6gI/s vs. 400 mg/ml: 2.0gI/s). Therefore, the higher attenuation values in the 400 mg/ml group might not be attributed to the CM concentration solely, but rather to the calculated product of CM concentration and injection rate (e. g. higher IDR).

Comparable results are reported by Cademartiri et al. [15] who evaluated coronary attenuation in five different CM groups where both injection rate and CM volume were kept identical. Mean attenuation values were significantly lower in the lower CM group and higher in the highly concentrated CM group. Again, due to the use of an identical injection rate in both groups, the IDR varied significantly (1.2 to 1.6gI/s), rendering doubtful conclusions with regard to the sole superiority of higher CM concentrations. The results of this systematic review show diagnostic attenuation levels of the RCA in the vast majority of the included studies when IDR levels ≥ 1.4gI/s were used and suggest that IDR levels are easier to modify through usage of a large variety in flow rates rather than a limited variety in CM concentrations (e. g. 270 – 400 mg/ml).

Recent studies have confirmed the hypothesis that a CM with a lower iodine concentration provides attenuation levels equal to those obtained using a more highly concentrated CM when the IDR is kept identical [76] [77]. In both in vivo and phantom studies, comparison of protocols using different CM concentrations (varying between 240 – 400 mg/ml) established comparable intravascular enhancement patterns when the IDR and other CM- and scan-related factors were kept standardized. These findings are supported by a double-blind randomized controlled study, in which both the objective and the subjective image quality were evaluated with usage of different iodine concentrations (e. g. 240 mg/ml, 300 mg/ml and 370 mg/ml) while maintaining an identical IDR and total iodine load [78]. In addition, patient comfort and pain at the injection site with usage of flow rates varying 5.4 – 8.3 ml/s and incidence of contrast extravasation have been evaluated. No significant differences were found between groups regarding comfort, stress, and pain [78]. This study also shows that the reluctance towards the usage of higher flow rates as a possible cause for an increased incidence of extravasation due to increased injection pressures is merely based on hypothetical flow-related issues. In a recent feasibility study, the latter was confirmed in an in vitro and in vivo setup [79]. The results from these studies confirm in a standardized way that the injection with high flow rates does not have any negative side effects. No extravasation or flow-related problems were observed and the maximum injection pressure of 325psi was not reached. As CMs with a lower concentration are attractive due to their lower viscosity and, hence, lower injection pressure, these findings might stimulate a shift in paradigm towards clinical usage of CMs with lower iodine concentrations (e. g. 240 mg/ml) for individually tailored contrast protocols with subsequently higher flow rates.

Attenuation values cannot be attributed to a saline flush and the product of CM concentration and flow rate solely. Lembcke et al. assessed the effect of lower CM volumes on image quality in high-pitch CCTA [74]. Patients were randomly assigned to one of five groups with different CM volumes (e. g. 30 – 70 ml). The flow rate and CM concentration remained identical in all groups (5 ml/s and 370 mg/ml, respectively). As the volumes in all groups were different, the calculated TID is also different (varying between 11.1 g and 25.9 g). They reported significantly higher mean attenuation values in groups with higher CM volumes [74]. An increased total CM volume injected at the same flow rate leads to a prolonged injection duration, which increases the magnitude of vascular enhancement. Similarly, injection of a dedicated CM with higher flow rates affects both the magnitude and timing of contrast enhancement, leading to a shorter, earlier and higher peak enhancement and a proportional increase in vascular and parenchymal enhancement [1] [4] [11] [80] [81]. A short injection duration might be challenging and requires careful timing of CM bolus injection and data acquisition, especially in patients with abnormal hemodynamic parameters (e. g. irregular heart rate or low/high cardiac output) [74]. The authors recommend taking into account the patient’s hemodynamic status, especially cardiac output, before imaging. Information regarding cardiac output has only been supplied in a very limited number of included publications [52] [64] [65] [68] [69] [70]. Body weight and BMI are known to have a substantial impact on vascular attenuation and time-to-peak in CTA [11] [82] [83] [84]. Many included publications evaluated the applicability of different body weight-adjusted CM injection or biphasic injection protocols with various outcomes. Seifarth et al. investigated whether individually tailored CM injection software resulted in higher vascular attenuation of coronary arteries compared to fixed injection protocols [55]. They evaluated a body weight adapted individualized CM injection software in comparison to two different standard injection protocols and found comparable or increased attenuation values in favor of the individualized CM injection software. However, besides overall mean attenuation of the coronary arteries between groups, an analysis for differences in attenuation values between weight classes was not performed. Another group evaluated the vascular attenuation of the coronary arteries as well as image quality and injection parameters within different weight classes by using identical body weight-adapted CM bolus injection software in comparison to a standardized injection protocol with fixed parameters [85]. Diagnostic attenuation in the entire coronary tree and a more homogeneous enhancement pattern between different weight groups was found with usage of the body weight-adapted injection software. The fixed injection protocol showed a large variation in the attenuation of the coronary arteries between different weight groups with higher attenuation levels in patients with a lower body weight and low attenuation levels in the heavier patients. These findings indicate suboptimal use of CM in different patient weight groups and show a clear benefit for individually tailored CM injection software in CCTA.

A thorough understanding of the influence of different injection parameters is considered a necessity for achieving the ultimate goal of individualized medicine. Disentangling the influence of patient-related parameters on attenuation and overall image quality will be helpful in defining optimal bolus shaping in future injection protocols, hereby creating a doorway towards individualized CM application. Though a large variation in IDR is applied in CCTA in the daily clinical routine, there is no literature or consensus regarding the optimal IDR for the attenuation of the coronary arteries. The goal is to create a personalized CM injection protocol, where some patients (e. g. lower weight and/or length or heart rate ≤ 60 bpm) might require less CM with a different scan timing protocol than other patients (e. g. higher BMI or heart rate ≥ 60 bpm) to reach the same attenuation value. Research needs to be directed towards defining individualized optimal IDR tailored towards patient-related factors (e. g. weight, heart rate, cardiac output) with further incorporation of different scan and injection parameters into computer modeling software.

This study has several limitations. The study population inclusion criterion was set to a minimum of 30 patients. Furthermore, a limited number of prospective randomized trials are available on this topic. A known limitation in all systematic reviews is that studies with less favorable results have a tendency not to be published. A publication bias, therefore, cannot be ruled out. Another potential limitation is the heterogeneity of vendors and scanner types. Although technical advances have improved image quality substantially, image quality can vary between vendors and scanner types. Most studies provided only limited data concerning injection, scanning, and patient parameters. Not all corresponding authors of the included articles completed and sent back the questionnaire or provided additional information. Therefore, possible effects of patient level characteristics (e. g. BMI, cardiac output) could not be accounted for. Nevertheless, these factors have a significant impact in the clinical routine and should be addressed by individualized scan and CM injection protocols. Finally, most of the included studies were scanned with a tube voltage of 120 kV. The use of lower kV settings subsequently leads to a higher contrast enhancement, as a lower tube voltage translates into lower effective photon energy, bringing the latter closer to the K-edge of iodine (33.2keV) [86] [87]. Technical developments of the CT technique have made the use of lower tube voltage (kV) possible. Using the newest CT technology has made kV settings as low as 70 kV and 80 kV feasible, also for a broader range of patients, as a higher tube current (mA) is available. These technical developments add to the importance of adapting CM injections. As current technical developments are moving towards broad clinical application of lower kV settings, a substantial decrease in various determinant injection parameters (e. g. IDR, CM volume) is expected.

 

MissingLinkText

Conclusion

This systematic review shows that an adequate attenuation in the coronary arteries can be achieved with different CM injection protocols. Given the substantial variability between studies, it remains unclear which of the injection parameters is the most important determinant for adequate attenuation. It is highly likely that one parameter that combines multiple parameters (e. g. IDR) will be the most determinant factor for coronary attenuation in CCTA protocols. Research needs to be directed towards unraveling the influence of injection parameters and defining individualized optimal IDRs tailored to patient-related factors. This will make it possible to offer a CM injection protocol with applicability of a broad variety of injection and scan-related parameters tailored to each individual patient.

List of abbreviations

CCTA: Coronary Computed Tomographic Angiography

CM: Contrast Media

TID: Total Iodine Dose

HU: Hounsfield Units

IDR: Iodine Delivery Rate

MDCT: Multidetector Computed Tomography

BMI: Body Mass Index

RCA: Right Coronary Artery

LAD: Left Anterior Descending artery

Cx: Circumflex artery

 

MissingLinkText

 

MissingLinkText

No conflict of interest has been declared by the author(s).

• References

• 1 Bae KT. Intravenous contrast medium administration and scan timing at CT: considerations and approaches. Radiology 2010; 256: 32-61
• 2 Otero HJ. Steigner ML. Rybicki FJ. The "post-64" era of coronary CT angiography: understanding new technology from physical principles. Radiologic clinics of North America 2009; 47: 79-90
• 3 Achenbach S. Marwan M. Schepis T. et al. High-pitch spiral acquisition: a new scan mode for coronary CT angiography. Journal of cardiovascular computed tomography 2009; 3: 117-121
• 4 Bae KT. Optimization of contrast enhancement in thoracic MDCT. Radiologic clinics of North America 2010; 48: 9-29
• 5 Budoff MJ. Dowe D. Jollis JG. et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (assessment by coronary computed tomographic angiography of individuals undergoing invasive coronary angiography) trial. Journal of the American College of Cardiology 2008; 52: 1724-1732
• 6 Meijboom WB. Meijs MF. Schuijf JD. et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. Journal of the American College of Cardiology 2008; 52: 2135-2144
• 7 Isogai T. Jinzaki M. Tanami Y. et al. Body weight-tailored contrast material injection protocol for 64-detector row computed tomography coronary angiography. Japanese journal of radiology 2011; 29: 33-38
• 8 Cademartiri F. Mollet NR. Lemos PA. et al. Higher intracoronary attenuation improves diagnostic accuracy in MDCT coronary angiography. American journal of roentgenology 2006; 187: W430-W433
• 9 Cademartiri F. Maffei E. Palumbo AA. et al. Influence of intra-coronary enhancement on diagnostic accuracy with 64-slice CT coronary angiography. European radiology 2008; 18: 576-583
• 10 Johnson PT. Pannu HK. Fishman EK. IV contrast infusion for coronary artery CT angiography: literature review and results of a nationwide survey. American journal of roentgenology 2009; 192: W214-W221
• 11 Awai K. Hiraishi K. Hori S. Effect of contrast material injection duration and rate on aortic peak time and peak enhancement at dynamic CT involving injection protocol with dose tailored to patient weight. Radiology 2004; 230: 142-150
• 12 Muhlenbruch G. Behrendt FF. Eddahabi MA. et al. Which iodine concentration in chest CT? A prospective study in 300 patients. European radiology 2008; 18: 2826-2832
• 13 Behrendt FF. Bruners P. Keil S. et al. Impact of different vein catheter sizes for mechanical power injection in CT: in vitro evaluation with use of a circulation phantom. Cardiovascular and interventional radiology 2009; 32: 25-31
• 14 Knollmann F. Schimpf K. Felix R. Iodine delivery rate of different concentrations of iodine-containing contrast agents with rapid injection. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 2004; 176: 880-884
• 15 Cademartiri F. Mollet NR. van der Lugt A. et al. Intravenous contrast material administration at helical 16-detector row CT coronary angiography: effect of iodine concentration on vascular attenuation. Radiology 2005; 236: 661-665
• 16 Cademartiri F. de Monye C. Pugliese F. et al. High iodine concentration contrast material for noninvasive multislice computed tomography coronary angiography: iopromide 370 versus iomeprol 400. Investigative radiology 2006; 41: 349-353
• 17 Brunette J. Mongrain R. Laurier J. et al. 3D flow study in a mildly stenotic coronary artery phantom using a whole volume PIV method. Medical engineering & physics 2008; 30: 1193-1200
• 18 Nance Jr JW. Henzler T. Meyer M. et al. Optimization of contrast material delivery for dual-energy computed tomography pulmonary angiography in patients with suspected pulmonary embolism. Investigative Radiology 2012; 47: 78-84
• 19 Rist C. Nikolaou K. Kirchin MA. et al. Contrast bolus optimization for cardiac 16-slice computed tomography: comparison of contrast medium formulations containing 300 and 400 milligrams of iodine per milliliter. Investigative radiology 2006; 41: 460-467
• 20 Behrendt FF. Pietsch H. Jost G. et al. Identification of the iodine concentration that yields the highest intravascular enhancement in MDCT angiography. American journal of roentgenology 2013; 200: 1151-1156
• 21 Moher D. Liberati A. Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of clinical epidemiology 2009; 62: 1006-1012
• 22 Whiting PF. Rutjes AW. Westwood ME. et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of internal medicine 2011; 155: 529-536
• 23 Malayeri AA. Zimmerman SL. Lake ST. et al. 128-Slice dual source coronary CTA: defining optimal arterial enhancement levels. Emergency radiology 2014; 21: 499-504
• 24 Becker CR. Hong C. Knez A. et al. Optimal contrast application for cardiac 4-detector-row computed tomography. Investigative radiology 2003; 38: 690-694
• 25 Cademartiri F. Luccichenti G. Marano R. et al. Comparison of monophasic vs biphasic administration of contrast material in non-invasive coronary angiography using a 16-row multislice computed tomography. La Radiologia Medica 2004; 107: 489-496
• 26 Cademartiri F. Luccichenti G. Marano R. et al. Use of saline chaser in the intravenous administration of contrast material in non-invasive coronary angiography with 16-row multislice Computed Tomography. La Radiologia Medica 2004; 107: 497-505
• 27 Cao L. Du X. Li P. et al. Multiphase contrast-saline mixture injection with dual-flow in 64-row MDCT coronary CTA. European journal of radiology 2009; 69: 496-499
• 28 Fuchs TA. Stehli J. Bull S. et al. Coronary computed tomography angiography with model-based iterative reconstruction using a radiation exposure similar to chest X-ray examination. European heart journal 2014; 35: 1131-1136
• 29 Hein PA. Romano VC. Lembcke A. et al. Initial experience with a chest pain protocol using 320-slice volume MDCT. European radiology 2009; 19: 1148-1155
• 30 Christensen JD. Meyer LT. Hurwitz LM. et al. Effects of iopamidol-370 versus iodixanol-320 on coronary contrast, branch depiction, and heart rate variability in dual-source coronary MDCT angiography. American journal of roentgenology 2011; 197: W445-W451
• 31 Kalafut JF. Kemper CA. Suryani P. et al. A personalized and optimal approach for dosing contrast material at coronary computed tomography angiography. Conference proceedings: annual international conference of the IEEE engineering in medicine and biology society IEEE engineering in medicine and biology society conference. 2009: 3521-3524
• 32 Kidoh M. Nakaura T. Nakamura S. et al. Low-contrast-dose protocol in cardiac CT: 20% contrast dose reduction using 100 kVp and high-tube-current-time setting in 256-slice CT. Acta radiologica 2014; 55: 545-553
• 33 Kidoh M. Nakaura T. Nakamura S. et al. Contrast material and radiation dose reduction strategy for triple-rule-out cardiac CT angiography: feasibility study of non-ECG-gated low kVp scan of the whole chest following coronary CT angiography. Acta radiologica 2014; 55: 1186-1196
• 34 Komatsu S. Kamata T. Imai A. et al. Coronary computed tomography angiography using ultra-low-dose contrast media: radiation dose and image quality. The international journal of cardiovascular imaging 2013; 29: 1335-1340
• 35 Li S. Liu J. Peng L. et al. Contrast volume reduction adapted to body mass index for 320-slice coronary computed tomography angiography: results from four-year clinical routine at a single center. International journal of cardiology 2014; 172: e140-e142
• 36 Litmanovich D. Zamboni GA. Hauser TH. et al. ECG-gated chest CT angiography with 64-MDCT and tri-phasic iv contrast administration regimen in patients with acute non-specific chest pain. European radiology 2008; 18: 308-317
• 37 Mitsumori LM. Wang E. May JM. et al. Triphasic contrast bolus for whole-chest ECG-gated 64-MDCT of patients with nonspecific chest pain: evaluation of arterial enhancement and streak artifact. American journal of roentgenology 2010; 194: W263-W271
• 38 Rienmuller R. Brekke O. Kampenes VB. et al. Dimeric versus monomeric nonionic contrast agents in visualization of coronary arteries. European journal of radiology 2001; 38: 173-178
• 39 Rutten A. Meijs MF. de Vos AM. et al. Biphasic contrast medium injection in cardiac CT: moderate versus high concentration contrast material at identical iodine flux and iodine dose. European radiology 2010; 20: 1917-1925
• 40 Stenzel F. Rief M. Zimmermann E. et al. Contrast agent bolus tracking with a fixed threshold or a manual fast start for coronary CT angiography. European radiology 2014; 24: 1229-1238
• 41 Tatsugami F. Husmann L. Herzog BA. et al. Evaluation of a body mass index-adapted protocol for low-dose 64-MDCT coronary angiography with prospective ECG triggering. American journal of roentgenology 2009; 192: 635-638
• 42 Wuest W. Anders K. Scharf M. et al. Which concentration to choose in dual flow cardiac CT?: dual flow cardiac CT. European journal of radiology 2012; 81: e461-e466
• 43 Yuki H. Utsunomiya D. Funama Y. et al. Value of knowledge-based iterative model reconstruction in low-kV 256-slice coronary CT angiography. Journal of cardiovascular computed tomography 2014; 8: 115-123
• 44 Cademartiri F. Mollet N. van der Lugt A. et al. Non-invasive 16-row multislice CT coronary angiography: usefulness of saline chaser. European radiology 2004; 14: 178-183
• 45 Cademartiri F. Luccichenti G. Gualerzi M. et al. Intravenous contrast material administration in multislice computed tomography coronary angiography. Acta biomedica 2005; 76: 86-94
• 46 Utsunomiya D. Awai K. Sakamoto T. et al. Cardiac 16-MDCT for anatomic and functional analysis: assessment of a biphasic contrast injection protocol. American journal of roentgenology 2006; 187: 638-644
• 47 Yamamuro M. Tadamura E. Kanao S. et al. Coronary angiography by 64-detector row computed tomography using low dose of contrast material with saline chaser: influence of total injection volume on vessel attenuation. Journal of computer assisted tomography 2007; 31: 272-280
• 48 Husmann L. Valenta I. Gaemperli O. et al. Feasibility of low-dose coronary CT angiography: first experience with prospective ECG-gating. European heart journal 2008; 29: 191-197
• 49 Kerl JM. Ravenel JG. Nguyen SA. et al. Right heart: split-bolus injection of diluted contrast medium for visualization at coronary CT angiography. Radiology 2008; 247: 356-364
• 50 Kim DJ. Kim TH. Kim SJ. et al. Saline flush effect for enhancement of aorta and coronary arteries at multidetector CT coronary angiography. Radiology 2008; 246: 110-115
• 51 Nakaura T. Awai K. Yauaga Y. et al. Contrast injection protocols for coronary computed tomography angiography using a 64-detector scanner: comparison between patient weight-adjusted- and fixed iodine-dose protocols. Investigative radiology 2008; 43: 512-519
• 52 Tsai IC. Lee T. Tsai WL. et al. Contrast enhancement in cardiac MDCT: comparison of iodixanol 320 versus iohexol 350. American journal of roentgenology 2008; 190: W47-W53
• 53 Wuest W. Zunker C. Anders K. et al. Functional cardiac CT imaging: a new contrast application strategy for a better visualization of the cardiac chambers. European journal of radiology 2008; 68: 392-397
• 54 Halpern EJ. Levin DC. Zhang S. et al. Comparison of image quality and arterial enhancement with a dedicated coronary CTA protocol versus a triple rule-out coronary CTA protocol. Academic radiology 2009; 16: 1039-1048
• 55 Seifarth H. Puesken M. Kalafut JF. et al. Introduction of an individually optimized protocol for the injection of contrast medium for coronary CT angiography. European radiology 2009; 19: 2373-2382
• 56 Kim EY. Yeh DW. Choe YH. et al. Image quality and attenuation values of multidetector CT coronary angiography using high iodine-concentration contrast material: a comparison of the use of iopromide 370 and iomeprol 400. Acta radiologica 2010; 51: 982-989
• 57 Lu JG. Lv B. Chen XB. et al. What is the best contrast injection protocol for 64-row multi-detector cardiac computed tomography?. European journal of radiology 2010; 75: 159-165
• 58 Ozbulbul NI. Yurdakul M. Tola M. Comparison of a low-osmolar contrast medium, iopamidol, and an iso-osmolar contrast medium, iodixanol, in MDCT coronary angiography. Coronary artery disease 2010; 21: 414-419
• 59 Pazhenkottil AP. Husmann L. Buechel RR. et al. Validation of a new contrast material protocol adapted to body surface area for optimized low-dose CT coronary angiography with prospective ECG-triggering. The international journal of cardiovascular imaging 2010; 26: 591-597
• 60 Tatsugami F. Matsuki M. Inada Y. et al. Feasibility of low-volume injections of contrast material with a body weight-adapted iodine-dose protocol in 320-detector row coronary CT angiography. Academic radiology 2010; 17: 207-211
• 61 Tatsugami F. Kanamoto T. Nakai G. et al. Reduction of the total injection volume of contrast material with a short injection duration in 64-detector row CT coronary angiography. The British journal of radiology 2010; 83: 35-39
• 62 Becker CR. Vanzulli A. Fink C. et al. Multicenter comparison of high concentration contrast agent iomeprol-400 with iso-osmolar iodixanol-320: contrast enhancement and heart rate variation in coronary dual-source computed tomographic angiography. Investigative radiology 2011; 46: 457-464
• 63 Kumamaru KK. Steigner ML. Soga S. et al. Coronary enhancement for prospective ECG-gated single R-R axial 320-MDCT angiography: comparison of 60- and 80-mL iopamidol 370 injection. American journal of roentgenology 2011; 197: 844-850
• 64 Nakaura T. Awai K. Yanaga Y. et al. Low-dose contrast protocol using the test bolus technique for 64-detector computed tomography coronary angiography. Japanese journal of radiology 2011; 29: 457-465
• 65 Zhu X. Chen W. Li M. et al. Contrast material injection protocol with the flow rate adjusted to the heart rate for dual source CT coronary angiography. The international journal of cardiovascular imaging 2012; 28: 1557-1565
• 66 Zhu X. Zhu Y. Xu H. et al. Dual-source CT coronary angiography involving injection protocol with iodine load tailored to patient body weight and body mass index: estimation of optimal contrast material dose. Acta Radiol 2013; 54: 149-155
• 67 Zhu X. Zhu Y. Xu H. et al. The influence of body mass index and gender on coronary arterial attenuation with fixed iodine load per body weight at dual-source CT coronary angiography. Acta radiologica 2012; 53: 637-642
• 68 Kidoh M. Nakaura T. Awai K. et al. Compact-bolus dynamic CT protocol with a test bolus technique in 64-MDCT coronary angiography: comparison of fixed injection rate and duration protocol. Japanese journal of radiology 2013; 31: 115-122
• 69 Kidoh M. Nakaura T. Nakamura S. et al. Novel contrast-injection protocol for coronary computed tomographic angiography: contrast-injection protocol customized according to the patient's time-attenuation response. Heart and vessels 2014; 29: 149-155
• 70 Liu J. Gao J. Wu R. et al. Optimizing contrast medium injection protocol individually with body weight for high-pitch prospective ECG-triggering coronary CT angiography. The international journal of cardiovascular imaging 2013; 29: 1115-1120
• 71 Yang WJ. Chen KM. Liu B. et al. Contrast media volume optimization in high-pitch dual-source CT coronary angiography: feasibility study. The international journal of cardiovascular imaging 2013; 29: 245-252
• 72 Tomizawa N. Suzuki F. Akahane M. et al. Effect of saline flush on enhancement of proximal and distal segments using 320-row coronary CT angiography. European journal of radiology 2013; 82: 1255-1259
• 73 Zheng M. Liu Y. Wei M. et al. Low concentration contrast medium for dual-source computed tomography coronary angiography by a combination of iterative reconstruction and low-tube-voltage technique: feasibility study. European journal of radiology 2014; 83: e92-e99
• 74 Lembcke A. Schwenke C. Hein PA. et al. High-pitch dual-source CT coronary angiography with low volumes of contrast medium. European radiology 2014; 24: 120-127
• 75 Kawaguchi N. Kurata A. Kido T. et al. Optimization of coronary attenuation in coronary computed tomography angiography using diluted contrast material. Circulation journal: official journal of the Japanese circulation society 2014; 78: 662-670
• 76 Mihl C. Wildberger JE. Jurencak T. et al. Intravascular enhancement with identical iodine delivery rate using different iodine contrast media in a circulation phantom. Investigative radiology 2013; 48: 813-818
• 77 Mihl C. Kok M. Wildberger JE. et al. Coronary CT angiography using low concentrated contrast media injected with high flow rates: feasible in clinical practice. European journal of radiology 2015; 84: 2155-2160
• 78 Kok M. Mihl C. Hendriks BM. et al. Patient comfort during contrast media injection in coronary computed tomographic angiography using varying contrast media concentrations and flow rates: results from the EICAR trial. Investigative radiology 2016;
• 79 Mihl C. Kok M. Wildberger JE. et al. Computed tomography angiography with high flow rates: an in vitro and in vivo feasibility study. Investigative radiology 2015; 50: 464-469
• 80 Schoellnast H. Deutschmann HA. Berghold A. et al. MDCT angiography of the pulmonary arteries: influence of body weight, body mass index, and scan length on arterial enhancement at different iodine flow rates. American journal of roentgenology 2006; 187: 1074-1078
• 81 Bae KT. Heiken JP. Scan and contrast administration principles of MDCT. European radiology 2005; 15: E46-E59
• 82 Bae KT. Seeck BA. Hildebolt CF. et al. Contrast enhancement in cardiovascular MDCT: effect of body weight, height, body surface area, body mass index, and obesity. American journal of roentgenology 2008; 190: 777-784
• 83 Platt JF. Reige KA. Ellis JH. Aortic enhancement during abdominal CT angiography: correlation with test injections, flow rates, and patient demographics. American journal of roentgenology 1999; 172: 53-56
• 84 Husmann L. Leschka S. Boehm T. et al. Influence of body mass index on coronary artery opacification in 64-slice CT angiography. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 2006; 178: 1007-1013
• 85 Mihl C. Kok M. Altintas S. et al. Evaluation of individually body weight adapted contrast media injection in coronary CT-angiography. European journal of radiology 2016; 85: 830-836
• 86 Mahesh M. MDCT physics: the basics: technology, image quality and radiation dose. 1st ed. Philadelphia: Lippincott Williams and Wilkins; 2009
• 87 Brooks RA. A quantitative theory of the Hounsfield unit and its application to dual energy scanning. Journal of computer assisted tomography 1977; 1: 487-493